Cosentyx (secukinumab) is the first IL-17A inhibitor to be available for moderate to severe plaque psoriasis in the UK

Novartis Pharmaceuticals UK Limited (Novartis) has announced that Cosentyx (secukinumab) is available for use in the UK for the treatment of moderate to severe plaque psoriasis in adults who...